Professor Michael Barry:

We either want to assess products and ensure we are getting value for money or we do not. If we do not assess drugs, we will pay the asking price for them. I believe that when we are using taxpayers' money, we should be looking for value and should assess the medications. That is my personal view. It was a very prominent statement from the FDA in the United States to clarify it did not believe this drug worked very well and would not authorise it.